Fujirebio Diagnostics Inc - Product Pipeline Analysis, 2019 Update

Published by Global Data on 12th November 2019 | Ref: 1463914 | This Product Is In Stock

$750 | Single User
$1500 | Site License
$2250 | Global License
$750 | Single User
$1500 | Site License
$2250 | Global License

Introduction

Summary

Fujirebio Diagnostics Inc (FDI), a subsidiary of Fujirebio Inc is a healthcare diagnostic company that manufactures, markets and develops biomarker assays and in-vitro diagnostic products. The company’s products include OEM custom solutions, manual kits, serum products, multi-constituent controls, EIA kits, and other test kits, among others. Its serum products comprise enzyme conjugate stabilizer, glycated human hemoglobin animal serums, and nonglycated human haemoglobin, among others. FDI also provides reagents and controls, and manual assay products, among others. The company offers elisa antibody and antigen kits. It has its operations through its offices located in the US, Italy and Russia. FDI is headquartered in Malvern, Pennsylvania, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Fujirebio Diagnostics Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Fujirebio Diagnostics Inc Company Overview

Fujirebio Diagnostics Inc Company Snapshot

Fujirebio Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview

Fujirebio Diagnostics Inc – Pipeline Analysis Overview

Fujirebio Diagnostics Inc - Key Facts

Fujirebio Diagnostics Inc - Major Products and Services

Fujirebio Diagnostics Inc Pipeline Products by Development Stage

Fujirebio Diagnostics Inc Pipeline Products Overview

Lumipulse G - AFP Assay

Lumipulse G - AFP Assay Product Overview

Lumipulse G - ApoB48 Assay Kit

Lumipulse G - ApoB48 Assay Kit Product Overview

Lumipulse G - CA15-3 Assay Kit

Lumipulse G - CA15-3 Assay Kit Product Overview

Lumipulse G - CA19-9 Assay

Lumipulse G - CA19-9 Assay Product Overview

Lumipulse G - CEA Assay

Lumipulse G - CEA Assay Product Overview

Lumipulse G - CYFRA Assay

Lumipulse G - CYFRA Assay Product Overview

Lumipulse G - Free PSA Assay

Lumipulse G - Free PSA Assay Product Overview

Lumipulse G - HAVAb Assay Kit

Lumipulse G - HAVAb Assay Kit Product Overview

Lumipulse G - HAVIgM Assay Kit

Lumipulse G - HAVIgM Assay Kit Product Overview

Lumipulse G - HBcIgM Assay Kit

Lumipulse G - HBcIgM Assay Kit Product Overview

Lumipulse G - HBcrAg Assay Kit

Lumipulse G - HBcrAg Assay Kit Product Overview

Lumipulse G - HbeAg Assay Kit

Lumipulse G - HbeAg Assay Kit Product Overview

Lumipulse G - HBsAb Assay Kit

Lumipulse G - HBsAb Assay Kit Product Overview

Lumipulse G - HBsAg-Qualitative Assay Kit

Lumipulse G - HBsAg-Qualitative Assay Kit Product Overview

Lumipulse G - HBsAg-Qualitative Confirmation Assay

Lumipulse G - HBsAg-Qualitative Confirmation Assay Product Overview

Lumipulse G - HBsAg-Quant Assay Kit

Lumipulse G - HBsAg-Quant Assay Kit Product Overview

Lumipulse G - HBsAg-Quant Confirmation Assay Kit

Lumipulse G - HBsAg-Quant Confirmation Assay Kit Product Overview

Lumipulse G - HCV Ab Assay Kit

Lumipulse G - HCV Ab Assay Kit Product Overview

Lumipulse G - HCV Ag Assay Kit

Lumipulse G - HCV Ag Assay Kit Product Overview

Lumipulse G - HIV 1/2 Assay Kit

Lumipulse G - HIV 1/2 Assay Kit Product Overview

Lumipulse G - HIV-1p24 Assay Kit

Lumipulse G - HIV-1p24 Assay Kit Product Overview

Lumipulse G - HIVAg/Ab Assay Kit

Lumipulse G - HIVAg/Ab Assay Kit Product Overview

Lumipulse G - HTLV-l Assay Kit

Lumipulse G - HTLV-l Assay Kit Product Overview

Lumipulse G - IL-6 Assay

Lumipulse G - IL-6 Assay Product Overview

Lumipulse G - L- FABP Assay

Lumipulse G - L- FABP Assay Product Overview

Lumipulse G - NCC-ST439 Assay

Lumipulse G - NCC-ST439 Assay Product Overview

Lumipulse G - PIVKA-II Assay

Lumipulse G - PIVKA-II Assay Product Overview

Lumipulse G - PLAP Assay Kit

Lumipulse G - PLAP Assay Kit Product Overview

Lumipulse G - PSA Assay Kit

Lumipulse G - PSA Assay Kit Product Overview

Lumipulse G - ß2M (S) Assay

Lumipulse G - ß2M (S) Assay Product Overview

Lumipulse G - ß2M (U) Assay

Lumipulse G - ß2M (U) Assay Product Overview

Lumipulse G - TP Assay

Lumipulse G - TP Assay Product Overview

Lumipulse G C-Peptide Assay Kit

Lumipulse G C-Peptide Assay Kit Product Overview

Lumipulse G Mesothelin Assay

Lumipulse G Mesothelin Assay Product Overview

Lumipulse G1200 - AMH

Lumipulse G1200 - AMH Product Overview

Lumipulse G1200 - Estradiol Assay

Lumipulse G1200 - Estradiol Assay Product Overview

Lumipulse G1200 - HTLV I/II Test

Lumipulse G1200 - HTLV I/II Test Product Overview

Lumipulse G1200 - pTAU

Lumipulse G1200 - pTAU Product Overview

Lumipulse G1200 - ß-amyloid 1-42

Lumipulse G1200 - ß-amyloid 1-42 Product Overview

Lumipulse G1200 - Testosterone Assay

Lumipulse G1200 - Testosterone Assay Product Overview

Lumipulse G1200 - Total TAU

Lumipulse G1200 - Total TAU Product Overview

Fujirebio Diagnostics Inc - Key Competitors

Fujirebio Diagnostics Inc - Key Employees

Fujirebio Diagnostics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Fujirebio Diagnostics Inc, Recent Developments

Jun 12, 2018: Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay

Apr 05, 2017: Fujirebio Europe Launches Lumipulse G HTLV-I/II for Fully Automated Screening of HTLV-I/II Viral Infection

Feb 19, 2016: Fujirebio Europe Launches Lumipulse G Mesothelin, The First Fully Automated Immunoassay to Aid in the Diagnosis of Malignant Mesothelioma

Jan 11, 2016: Fujirebio Europe launches Lumipulse G B•R•A•H•M•S PCT for fully automated testing on theLUMIPULSE G series

Jun 18, 2015: Fujirebio Europe Releases The Lumipulse G He4 Assay Dedicated To Ovarian Cancer Therapy Monitoring And Conservative Management Of Women With Pelvic Mass

Sep 06, 2011: Fujirebio Receives FDA 510 (k) Clearance For ROMA (HE4 EIA + ARCHITECT CA 125 II) Test To Monitor Ovarian Cancer

Jun 06, 2011: Fujirebio Reports New Publication Validates Use Of HE4 In Evaluating Risk Of Ovarian Cancer

May 31, 2011: Fujirebio Receives FDA 510 (k) Clearance For CYFRA 21-1 EIA Assay To Monitor Lung Cancer

Mar 23, 2009: Fujirebio Diagnostics Appoints Grady Barnes As CSO

Feb 11, 2009: Fujirebio Diagnostics` Risk Of Ovarian Malignancy Algorithm(ROMA) In Combination With Biomarker Demonstrates Accuracy In Detecting Ovarian Cancer

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

Additional Details

Publisher

Global Data

Publisher Information

Reference

1463914 | GDME2171PD

Number of Pages

66

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

This report is published by Global Data

Global Data deliver comprehensive, detailed market intelligence that provides a definitive picture of the markets they serve. Their data is complete, detailed, global and completely cross-country comparable.

With different types of data other providers don’t provide, our clients can access a variety of tools that add context to our core data including innovation tracking, sentiment analysis, price monitoring, M&A tracking, competitor intelligence, and city-level intelligence.

Download Free Report Summary PDF

Fujirebio Diagnostics Inc - Product Pipeline Analysis, 2019 Update | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.